SHR3162 is an investigational drug.
There have been 20 clinical trials for SHR3162.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Atridia Pty Ltd.
There are two US patents protecting this investigational drug and twenty-one international patents.